Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2017-06-10
Buyer: Sykehusinnkjøp HF
Country: NO
Region: Oslo og Akershus
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 3200000 NOK
Award criteria: Lowest price

Technical requirements: The procurement comprises the purchase of the active ingredient pantoprazol for all of the health authorities in Norway. The Contracting Authority intends to enter into into an agreement with Takeda AS. This procurement is the consequence of the termination of the existing agreement on the active ingredient pantoprazol under LIS 1701A due to long term and continued delivery failure. The reason a procurement process wasn't started at an earlier point in time is that the Contracting Authority had reason to believe tat the delivery failure would not persist.
To cover the health authorities' need for the active ingredient pantoprazol it is necessary to enter into a new framework agreement. A new procurement process will take about 2 months to execute, and a new tenderer will additionally need a lead time of 3 months from awarding of the agreement until delivery can occur. A new agreement will therefore most likely not be in place before November, after a regular tender process. With the execution of a regular tender process, the health authorities must wait an unreasonable length of time before the new supplier is in place. The existing agreements under LIS 1701 A are in place until 31.1.2018, and a new agreement for the active ingredient pantoprazol will therefore, after a regular tender process, only have a duration of a little under three months. According to the plan, a new procurement process will be started for the entirety of this agreement area in August 2017, as the new framework agreements should be valid from 1.2.2018. It is therefore considered unlikely that there will be any interested parties in the supplier market to participate in a regular tender process for just the active ingredient pantoprazol when the agreement period is only three months. In connection with the purchase of the active substance pantoprazol, the Contracting Authority has asked all suppliers that the Contracting Authority has knowledge of in the market and who may be relevant for the delivery of this active substance. Takeda AS is the only supplier who has confirmed that they can deliver.
On this basis, the Contracting Authority means that it would be impossible to uphold the deadline for an open tender contest as a consequence of circumstances for which the Contracting Authority is not responsible, and that the Contracting Authority cannot foresee, and that there is statutory basis to enter into an agreement with Takeda AS for the active ingredient pantoprazol.
The procurement comprises the purchase of the active ingredient pantoprazol for all of the health authorities in Norway. The Contracting Authority intends to enter into into an agreement with Takeda AS. This procurement is the consequence of the termination of the existing agreement on the active ingredient pantoprazol under LIS 1701A due to long term and continued delivery failure. The reason a procurement process wasn't started at an earlier point in time is that the Contracting Authority had reason to believe tat the delivery failure would not persist.
In order to cover the health authorities' need for for the active ingredient pantoprazol, it is therefore necessary to enter into a new framework agreement. A new procurement process will take about 2 months to execute, and a new tenderer will additionally need a lead time of three months from awarding of the agreement until delivery can occur. A new agreement will therefore most likely not be in place before November, after a regular tender process. With the execution of a regular tender process, the health authorities must wait an unreasonable length of time before the new supplier is in place. The existing agreements under LIS 1701 A are in place until 31.1.2018, and a new agreement for the active ingredient pantoprazol will therefore, after a regular tender process, only have a duration of a little under three months. According to the plan, a new procurement process will be started for the entirety of this agreement area in August 2017, as the new framework agreements should be valid from 1.2.2018. It is therefore considered unlikely that there will be any interested parties in the supplier market to participate in a regular tender process for just the active ingredient pantoprazol when the agreement period is only three months. In connection with the purchase of the active substance pantoprazol the Contracting Authority has asked all suppliers that the Contracting Authority has knowledge of in the market and who may be relevant for the delivery of this active substance. Takeda AS is the only supplier who has confirmed that they can deliver.
On this basis, the Contracting Authority means that it would be impossible to uphold the deadline for an open tender contest as a consequence of circumstances for which the Contracting Authority is not responsible, and that the Contracting Authority cannot foresee, and that there is statutory basis to enter into an agreement with Takeda AS for the active ingredient pantoprazol.


Winner: Takeda AS
Award value: 3200000